Employers Rethink GLP‑1 Coverage

# Employers Rethink GLP-1 Coverage Employers are moving from a simple question — “Do we cover glucagon-like peptide-1 drugs?” — to a harder one: “How do we cover them without blowing up the health plan?” A new 9amHealth Trend Report, based on a nationally representative December 2025 survey of more than 1,000 working-age U.S. adults, says use of these drugs has more than doubled since 2023 and now reaches 49% of respondents. (prnewswire.com) That shift matters because these medicines are no longer sitting at the edge of benefits strategy. In the 9amHealth survey, glucagon-like peptide-1 coverage ranked among the top three most valued workplace benefits for more than 40% of respondents, putting a drug benefit in the same conversation as core employer offerings that usually define job quality. (prnewswire.com) The labor-market angle is now hard to ignore. 9amHealth found that 30% of workers said they would change jobs to gain or keep access to these drugs, which means benefit design is starting to affect recruiting and retention in the same way retirement match formulas or family coverage once did. (prnewswire.com) The next problem is demand that has not even fully hit yet. Among employees without coverage, 93% said they would take a glucagon-like peptide-1 drug if their employer paid for it, suggesting that many companies are not budgeting for a steady trend line but for a possible surge the moment plan rules loosen. (prnewswire.com) Cost is the wall employers keep running into. More than half of respondents in the 9amHealth survey said price was the main barrier to starting or staying on treatment, even after a 5% increase in employer coverage and lower direct-to-consumer pricing. (prnewswire.com) Staying on the drugs is another weak point. In the same survey, more than 25% of respondents said they stopped treatment because of side effects, and a January 2025 study in *JAMA Network Open* found that among 125,474 adults starting these medicines, 64.8% of patients without type 2 diabetes discontinued within one year. (prnewswire.com) (jamanetwork.com) That discontinuation data helps explain why employers are rethinking the old model of writing a big pharmacy check and hoping for the best. If a company pays for an expensive drug but members stop early, cycle back on later, or never get support around food, exercise, and side-effect management, the plan can end up buying a very costly start-stop pattern instead of durable health improvement. (jamanetwork.com) (prnewswire.com) That is why the 9amHealth report argues for “clinical guardrails” instead of open-ended access alone. Its core recommendation is to pair medication coverage with clinician oversight, behavior-change support, and cost-management tools so the employer is not just financing prescriptions but managing a chronic condition the way it would manage diabetes or hypertension. (prnewswire.com) Outside research points in the same direction. Aon’s second-phase workforce analysis, using claims data from about 50 million commercially insured lives and a nationally representative sample of 192,000 users, found that people who maintained at least 80% adherence saw greater cost reductions and better outcomes than less-adherent users. (aon.com) Aon also found that after an initial rise, medical cost growth for glucagon-like peptide-1 users slowed relative to matched non-users over 18 months for weight loss and 30 months for diabetes. That does not mean every employer saves money immediately, but it does suggest the economics depend heavily on who gets treated, how long they stay on therapy, and whether the program keeps them engaged long enough for downstream savings to appear. (aon.com) Employers are still cautious for a reason. KFF’s 2025 employer discussions found that large firms were becoming more willing to cover these drugs for weight loss, but many reported higher-than-expected use and a significant jump in prescription drug spending once coverage was available. (healthsystemtracker.org) The scale of the underlying health problem is part of what keeps this debate moving. KFF estimates that 34% of non-elderly people with employer-sponsored insurance — about 36.2 million people — have a body mass index that would medically qualify them for a glucagon-like peptide-1 drug, which means even narrow eligibility rules can still expose employers to very large potential demand. (healthsystemtracker.org) The fiscal backdrop is even larger than the benefits debate. A 2024 Joint Economic Committee Republican response estimated obesity could drive $8.2 trillion to $9.1 trillion in excess medical spending over the next decade, a range that has become a common reference point in employer and policy discussions about treatment access. (jec.senate.gov) So the new argument is not really “cover” versus “don’t cover.” It is whether employers can build a benefits program that treats these drugs less like a one-time perk and more like a managed long-term therapy, with eligibility rules, coaching, monitoring, and follow-up designed to keep outcomes improving while costs stay inside the rails. (prnewswire.com) (aon.com) For benefits teams, that means the winning design may be narrower than employees want but more durable than broad, unmanaged access. For investors, it means the next phase of the glucagon-like peptide-1 market may reward the companies that help employers control adherence, side effects, and total cost of care — not just the companies that sell the drugs. (prnewswire.com) (aon.com)